Diagnostics

A Korean firm says it can cure 34 diseases using cells from cloned embryos, walking a fine line between a medical breakthrough and a bioethical taboo.

With strong growth in key sectors but weakness in others, Plexus management faces a pivotal moment at the upcoming Raymond James investor conference.

BioNexus Gene Lab appoints Matthew Barsing to lead its Chemrex subsidiary, signaling a strategic overhaul from industrial chemicals to biotech and advanced tech.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

A Malaysian biotech's new study shows its NK cell therapy is safe, using a novel, low-cost method that could make advanced cancer treatment affordable worldwide.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

A new three-tube collection system from BD promises to improve accuracy, streamline lab work, and enhance patient safety by reducing sample contamination.

TOMI Environmental Solutions secures crucial biocidal product approvals in Great Britain and NI, paving the way for a major European market expansion.

Beyond affordability, India is positioning itself as a trusted global health hub by blending modern medicine with ancient wisdom to fuel its economy.

The diagnostics firm has 180 days to boost its market value after a Nasdaq warning, placing immense pressure on its turnaround and high-stakes biosensor plans.

With stockholder approval, Abbott's acquisition of Exact Sciences is set to reshape the cancer diagnostics landscape and accelerate early detection.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

As Sectra prepares its nine-month report, all eyes are on its performance as a key indicator for the converging medical IT and cybersecurity sectors.

The behavioral analytics market is set to explode to over $6 billion by 2032, driven by AI's dual role in cybersecurity and personalized customer engagement.

Klothea Bio's trial for a 'longevity protein' drug in Honduras pushes the boundaries of science, but raises questions about offshore research and equity.

A new report reveals a healthcare system at odds with modern life, driving women to skip care. But at-home tech and new information sources are forcing a change.

At ViVE 2026, a live podcast aims to prove the future of medicine is not just in new drugs, but in the intelligence hidden within diagnostic data.

WellAve Dermatology opens a Mohs surgery center in Easton, bringing a top-tier surgeon and gold-standard cancer care to a medically underserved region.